UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

Core Viewpoint - GSK has committed to investing at least $30 billion in U.S. research and development (R&D) and manufacturing over the next five years, which includes a focus on advanced manufacturing and digital technologies [1][2]. Investment Commitment - The investment will include $1.2 billion specifically allocated for advanced manufacturing, artificial intelligence (AI), and advanced digital technologies to create next-generation biopharma factories and laboratories in the U.S. [1][2]. Context of the Announcement - This investment announcement coincides with President Donald Trump's state visit to the U.K., highlighting the collaboration between the two countries in science and healthcare innovation [2].